Alkem Labs Logs Operational Beat In Q3, Growing Strength To Strength: Dolat Capital

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

Alkem Laboratories Ltd. reported a better than expected Q3 on the operational front despite an in-line revenue growth of 6% YoY.

Better gross margins (lesser free samples) and higher contribution of trade generics aided Ebitda margin at 22.8% versus our expectation of 21.2%.

One-time income of Rs 340 million on sale of brand aided profit after tax at Rs 4.5 billion, 20% beat on our numbers.

While the acute portfolio is on a recovery mode, outperformance in trade generics rendered 6% YoY growth.

U.S. was steady at $84 million, up 5% YoY.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.